Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based
Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based imaging productand will compete with Du Pont Merck's Cardiolite agent. Medi-Physicswill emphasize the fast clearance of Myoview as well as the product'sease of use compared to thallium agents. Final FDA approval isexpected within a few months, according to the company.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.